List of Biodesix patents

Patents where

Current Assignee

Name

Biodesix

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9477906 Classification generation method using combination of mini-classifiers with regularization and uses thereof	Patent 9477906 was granted and assigned to Biodesix on October, 2016 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	9477906	October 25, 2016
‌ US Patent 10007766 Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods	Patent 10007766 was granted and assigned to Biodesix on June, 2018 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	10007766	June 26, 2018
‌ US Patent 11621057 Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy	Patent 11621057 was granted and assigned to Biodesix on April, 2023 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	11621057	April 4, 2023
‌ US Patent 11476003 Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings	Patent 11476003 was granted and assigned to Biodesix on October, 2022 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	11476003	October 18, 2022
‌ US Patent 9254120 Method for predicting breast cancer patient response to combination therapy	Patent 9254120 was granted and assigned to Biodesix on February, 2016 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	9254120	February 9, 2016
‌ US Patent 9279798 Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof	Patent 9279798 was granted and assigned to Biodesix on March, 2016 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	9279798	March 8, 2016
‌ US Patent 8024282 Method for reliable classification of samples in clinical diagnostics using an improved method of classification	Patent 8024282 was granted and assigned to Biodesix on September, 2011 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	8024282	September 20, 2011
‌ US Patent 9606101 Deep MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof	Patent 9606101 was granted and assigned to Biodesix on March, 2017 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	9606101	March 28, 2017
‌ US Patent 10217620 Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry	Patent 10217620 was granted and assigned to Biodesix on February, 2019 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	10217620	February 26, 2019
‌ US Patent 8467988 Method and system for validation of mass spectrometer machine performance	Patent 8467988 was granted and assigned to Biodesix on June, 2013 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	8467988	June 18, 2013
‌ US Patent 9211314 Treatment selection for lung cancer patients using mass spectrum of blood-based sample	Patent 9211314 was granted and assigned to Biodesix on December, 2015 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	9211314	December 15, 2015
‌ US Patent 8119417 Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samples	Patent 8119417 was granted and assigned to Biodesix on February, 2012 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	8119417	February 21, 2012
‌ US Patent 9563744 Method of predicting development and severity of graft-versus-host disease	Patent 9563744 was granted and assigned to Biodesix on February, 2017 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	9563744	February 7, 2017
‌ US Patent 8119418 Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples	Patent 8119418 was granted and assigned to Biodesix on February, 2012 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	8119418	February 21, 2012
‌ US Patent 8718996 Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents	Patent 8718996 was granted and assigned to Biodesix on May, 2014 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	8718996	May 6, 2014
‌ US Patent 8097469 Method and system for determining whether a drug will be effective on a patient with a disease	Patent 8097469 was granted and assigned to Biodesix on January, 2012 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	8097469	January 17, 2012
‌ US Patent 9152758 Method and system for determining whether a drug will be effective on a patient with a disease	Patent 9152758 was granted and assigned to Biodesix on October, 2015 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	9152758	October 6, 2015
‌ US Patent 9824182 Method and system for determining whether a drug will be effective on a patient with a disease	Patent 9824182 was granted and assigned to Biodesix on November, 2017 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	9824182	November 21, 2017
‌ US Patent 10338074 Compositions, methods and kits for diagnosis of lung cancer	Patent 10338074 was granted and assigned to Biodesix on July, 2019 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	10338074	July 2, 2019
‌ US Patent 10489550 Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample	Patent 10489550 was granted and assigned to Biodesix on November, 2019 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	10489550	November 26, 2019
‌ US Patent 9779204 Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample	Patent 9779204 was granted and assigned to Biodesix on October, 2017 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	9779204	October 3, 2017
‌ US Patent 11542340 Antibodies targeting pulmonary nodule specific biomarkers and uses thereof		Biodesix	Biodesix	United States Patent and Trademark Office	11542340	January 3, 2023
‌ US Patent 11467167 SRM methods in Alzheimer's disease and neurological disease assays		Biodesix	Biodesix	United States Patent and Trademark Office	11467167	October 11, 2022
‌ US Patent 10950348 Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods	Patent 10950348 was granted and assigned to Biodesix on March, 2021 by the United States Patent and Trademark Office.	Biodesix	Biodesix	United States Patent and Trademark Office	10950348	March 16, 2021
‌ US Patent 8914238 Method for predicting breast cancer patient response to endocrine therapy	Patent 8914238 was granted and assigned to Biodesix on December, 2014 by the United States Patent and Trademark Office.		Biodesix	United States Patent and Trademark Office	8914238	December 16, 2014

Results per page:

36 results

0 selected

36 results

0 selected